Tag: belantamab mafodotin
ASCO 2022: Belantamab Mafodotin in the Treatment of Patients with Relapsed/Refractory...
The treatment patients diagnosed with relapsed or relapsed/refractory multiple myeloma (RRMM), those who have relapsed or who are refractory to at least 1 line of...
ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in...
Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but not curable. Multiple myeloma...
The Story of World ADC Digital
As we plan ahead, for the upcoming digital World ADC Europe with much greater confidence, we were reflecting on what a year it has...
European Commission Grants Conditional Marketing Authorization to GSK for the Use...
The European Commission has granted conditional marketing authorization* for the use of GlaxoSmithKline's anti-B-cell maturation antigen (BCMA) therapy belantamab mafodotin (Blenrep®) as monotherapy for...
U.S. FDA Approves Belantamab Mafodotin as a Monotherapy in R/R Multiple...
The U.S. Food and Drug Administration has approved* belantamab mafodotin-blmf (Blenrep®; GlaxoSmithKline/GSK) as a monotherapy treatment for adult patients with relapsed or refractory multiple...
CHMP Adopts Positive Opinion for Belantamab Mafodotin, Recommending Approval for the...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of...
Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab...
The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive benefit/risk profile for belantamab mafodotin...
ASCO 2020 – Advancing Antibody-drug Conjugates: Belantamab Mafodotin
Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable. Research into new therapies is needed as...
Belantamab Mafodotin Receives Priority Review for Relapsed or Refractory Multiple Myeloma
The United States Food and Drug Administration (FDA) has granted a priority review of a Biologics License Application (BLA) for belantamab mafodotin (GSK2857916), a...
DREAMM-2 Trial Shows Positive Results for Belantamab Mafodotin in Multiple Myeloma
Earlier today positive headline results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916), an anti-BCMA antibody-drug conjugate or...
